glp-1 drug delivery devices Improving drug-like properties of insulin and via molecule design and formulation and improving diabetes management with device & US study suggests GLP-1 RA

intravenous L-arginine Arginine may activate N-acetylglutamate synthetase (NAGS), thereby counterbalancing the inhibitor effect of valproic acid metabolites

Toxicol Sci 176(2):410422

For blood glucose control in patients with type 2 diabetes, initial effects can often be observed within the first 1-2 weeks of treatment as the medication begins influencing insulin and glucagon secretion

Target two-hour after-meal (postprandial) glucose levels For people with diabetes whose A1C levels are not at goal despite fasting glucose levels being within the targeted range (80 130 mg/dL), the ADA suggests assessment of two-hour after-meal (postprandial) glucose levels, with a targeted level of less than 180 mg/dL (ADA 2021a)